arrow_back Back to App

End Drug Price Gouging: Lower Medication Costs for All

This bill aims to lower prescription drug prices by setting maximum prices based on costs in other countries. This means that medications for individuals covered by federal programs, as well as for uninsured individuals, could become more affordable. Manufacturers who do not comply will face penalties, with collected funds directed towards drug research.
Key points
Establishes maximum prescription drug prices based on the lowest prices in selected countries like Canada, Germany, or Japan.
Lower drug prices for individuals covered by Medicare, Medicaid, TRICARE, veterans' and federal employee programs, and for the uninsured.
Financial penalties for drug manufacturers who sell above the set price, with funds allocated to new drug research and development.
article Official text account_balance Process page
Introduced
Citizen Poll
No votes cast
Additional Information
Print number: 119_HR_3391
Sponsor: Rep. Dingell, Debbie [D-MI-6]
Process start date: 2025-05-14
Lustra uses Artificial Intelligence. Verify details in source documents.
Summarized by: gemini-2.5-flash-preview-05-20
Source data: api.congress.gov
AI work logs for this document launch

OFFICIAL LEGAL TITLE

End Price Gouging for Medications Act

FREQUENTLY ASKED QUESTIONS

What is the official ID of this bill?

The official print number for this legislation is 119_HR_3391.

Which chamber initiated this legislation?

This legislation was initiated in the House of Representatives.

When did the legislative process begin?

The process officially started on 2025-05-14.

What are the main provisions?

Key points include:

  • Establishes maximum prescription drug prices based on the lowest prices in selected countries like Canada, Germany, or Japan.
  • Lower drug prices for individuals covered by Medicare, Medicaid, TRICARE, veterans' and federal employee programs, and for the uninsured.
  • Financial penalties for drug manufacturers who sell above the set price, with funds allocated to new drug research and development.
What is the specific legal status?

The current status is Introduced.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Rep. Dingell, Debbie [D-MI-6].

What is the latest detailed status?

The latest detailed status is: Referred to the Subcommittee on Health.

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-22.

CATEGORIES

Health